Fluoroquinolones: Cipro, Levaquin & Avelox

Fluoroquinolones such as Cipro, Levaquin and Avelox are antibiotics approved to treat or prevent serious bacterial infections, including skin, bone and joint, lower respiratory tract and urinary tract infections. They work by killing or stopping the growth of certain bacteria.

Fluoroquinolones Pills
Cipro, Levaquin & Avelox Facts
  1. Used to Treat Certain bacterial infections
  2. Interactions Antacids, sucralfate, metal cations, multivitamins, warfarin, phenytoin, methotrexate, antidiabetic agents, non-steroidal anti-inflammatory drugs, theophylline, cyclosporine, digoxin, probenecid and cimetidine
  3. Active Ingredients Ciprofloxacin hydrochloride (Cipro), levofloxacin (Levaquin) and moxifloxacin hydrochloride (Avelox)
  4. Treatment Duration Seven to 60 days, depending on infection type
  5. FDA Approval Status Cipro-1987; Levaquin-1996; Avelox-1999

Researchers first discovered this family of antibiotics in the 1960s, but it wasn’t until the late 1980s that Cipro and other modern fluoroquinolones first hit the market.

At the time, doctors primarily prescribed the medications to treat urinary tract infections. Since then, they have become the go-to antibiotic for many infections.

In fact, American doctors wrote about 29.7 million fluoroquinolone antibiotic prescriptions in 2016, according to the Centers for Disease Control and Prevention’s most current statistics.

These drugs are potent, and the U.S. Food and Drug Administration approved them to treat or prevent serious bacterial infections, including anthrax, plague and bacterial pneumonia.

Other approved uses include the treatment of:
  • Skin and skin structure infections
  • Bone and joint infections
  • Complicated intra-abdominal infections
  • Infectious diarrhea
  • Typhoid fever (enteric fever)
  • Uncomplicated cervical and urethral gonorrhea
  • Chronic bacterial prostatitis
  • Lower respiratory tract infections
  • Urinary tract infections
  • Acute uncomplicated cystitis
  • Acute bacterial sinusitis
  • Acute pyelonephritis
  • Acute bacterial exacerbation of chronic bronchitis
  • Acute bacterial sinusitis.
Registered Nurse Amy Keller describes several uses of fluoroquinolones.

A 2016 FDA safety review found the antibiotics are associated with disabling side effects involving tendons, muscles, joints, nerves and the central nervous system. These side effects can occur hours to weeks after exposure to the drugs and may potentially be permanent, according to the agency. The most severe side effects of fluoroquinolones are considered rare. Some can be fatal.

The medications carry the FDA’s most serious warning, a black box warning, for tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects and exacerbation of myasthenia gravis. In December 2018, the FDA required a new warning about an increased risk of aortic ruptures or tears that can lead to dangerous bleeding or even death. People who suffered aortic injuries after taking fluoroquinolones have filed lawsuits over Cipro, Levaquin and Avelox.

Because of the risks, the FDA has announced that patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections should only use these medications when no alternative treatment options exist.

OVERUSING FLUOROQUINOLONES
Dr. Mahyar Etminan, an epidemiologist at the University of British Columbia, said overusing these drugs is like “trying to kill a fly with an automatic weapon.

As with other antibacterial drugs, fluoroquinolones do not treat viral infections such as colds, flu or bronchitis in people who are otherwise healthy. They should be used “only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria,” according to the drug’s label. This is to reduce the development of drug-resistant bacteria and to maintain the effectiveness of antibacterial drugs.

Dr. Lindsey R. Baden, an infectious disease doctor at Brigham and Women’s Hospital, agrees with the FDA. She told Consumer Reports that doctors often overprescribe fluoroquinolones because they work against many types of bacteria.

“Fluoroquinolones play an important role in treating serious infections such as those caused by bacteria that are resistant to other types of antibiotics,” Baden told Consumer Reports. But in the case of less serious infections, they “should typically be reserved for second-line or even third-line treatment after other antibiotics have failed,” she said.

Were you harmed by a fluoroquinolone antibiotic? Get a Free Case Review

How These Antibiotics Work

Fluoroquinolones work by directly interfering with bacterial DNA, according to an article by researcher Katie J. Aldred of the Department of Biochemistry and Department of Medicine at the Vanderbilt University School of Medicine. She and her colleagues wrote these types of drugs affect the enzymes gyrase and topoisomerase IV. These enzymes work to build bacterial DNA, but they may also break it. The antibiotics enhance the DNA-breaking qualities of these enzymes, turning them into toxic compounds that “poison” the cells.

Researchers believe the way these medications work also makes bacteria less likely to become resistant to them versus other antibiotics such as penicillin and tetracycline, according to an article by researcher David C. Hooper in Clinical Infectious Diseases. For example, bacteria that penicillin cannot kill may be susceptible to ciprofloxacin, according to the drug’s label.

Some bacteria fluoroquinolones fight include:
  • Bacillus anthracis
  • Campylobacter jejuni
  • Enterococcus faecalis
  • Klebsiella pneumoniae
  • Salmonella typhi
  • Streptococcus pneumoniae

Patients who take these antibiotics should drink a lot of fluids. They can take the medicine with or without food.

Types of Fluoroquinolones

Six fluoroquinolones are currently approved for use in United States in the form of pills, injections and topical creams: ciprofloxacin, ofloxacin, gemifloxacin, levofloxacin, moxifloxacin and delafloxacin.

The most popular brand name drugs in the class are:
  • Cipro and Cipro XR (ciprofloxacin)
  • Avelox (moxifloxacin)
  • Levaquin (levofloxacin)

Other fluoroquinolones such as Factive (gemifloxacin), Baxdela (delafloxacin) and the generic brand Ofloxacin are not as widely used. Maxaquin (lomefloxacin), Raxar (grepafloxacin hydrochloride) and Zagam (sparfloxacin) are no longer available in the United States.

Meanwhile, Merck discontinued its drug Noroxin (norfloxacin) in 2014. And Janssen Pharmaceuticals reported to the FDA that it would stop making Levaquin and Floxin (ofloxacin).

Cipro, Cipro XR, Proquin XR

Cipro is the most widely used of all the fluoroquinolones. From 2004 to 2010, retail pharmacies in the United States dispensed about 122.5 million prescriptions for the drug, according to pharmacists S. Christopher Jones and colleagues at the FDA’s Office of Surveillance and Epidemiology. In 2015 alone, doctors in the United States wrote 20.3 million prescriptions for the oral drug, according to the CDC’s most current data.

Ciprofloxacin, the active ingredient in Cipro, is also the active ingredient in the extended release versions, Cipro XR and Proquin XR. The FDA originally approved the drug in 1987. It is a second-generation fluoroquinolone. Doctors often prescribe it to treat mild-to-moderate respiratory and urinary tract infections, but it also treats other conditions, including gonorrhea, infectious diarrhea and anthrax.

Cipro Pills
Cipro tablets come in 250 mg and 500 mg strengths.
Cipro comes in the following formulas and doses:
Oral Tablets
100 mg, 250 mg, 500 mg and 750 mg
Extended-release tablets
500 mg and 1,000 mg (available only as generic)
Intravenous
200 mg to 400 mg
Oral Suspension
5% Oral Suspension: 250 mg ciprofloxacin per 5 ml after reconstitution

10% Oral Suspension: 500 mg ciprofloxacin per 5 ml after reconstitution

Levaquin

Levaquin is the second most popular drug in the class. From 2004 to 2010, Americans received about 88.1 million prescriptions for levofloxacin, according to the FDA’s Office of Surveillance and Epidemiology. It is a third-generation fluoroquinolone. The FDA originally approved the drug in 1996.

In 2010, it was the best-selling antibiotic in the United States, according to The New York Times. Like Cipro, it treats respiratory and urinary tract infections. It also treats other conditions, including plague, anthrax, bronchitis and pneumonia.

Levaquin Pills
Levaquin tablets come in 250 mg, 500 mg and 750 mg strengths.

Janssen Pharmaceuticals stopped making Levaquin, according to the FDA, though the agency does not specify why the drugmaker discontinued it. Although the company discontinued all versions of the brand name drug in December 2017, it may still be available in pharmacies until 2020, according to news outlet RTV6 in Indianapolis.

“The decision to discontinue Levaquin was made due to the wide availability of alternative treatment options, and our focus on developing innovative medicines designed to address unmet medical patient needs,” Kelsey Buckholtz, a spokeswoman for Janssen, told RTV6.

Generic levofloxacin is still available in the United States.

Avelox

The third-most-popular fluoroquinolone in the United States is Avelox, a fourth-generation medication. The FDA’s Office of Surveillance and Epidemiology estimates about 24.3 million people received prescriptions for moxifloxacin between 2004 and 2010.

The FDA approved the drug in 1999 to treat multiple drug-resistant types of Streptococcus pneumoniae, the bacteria that cause pneumonia, ear infections and meningitis, among other conditions. It also treats skin infections, cellulitis and intra-abdominal infections.

Avelox Pills
Avelox comes in 400 mg pills as well as an IV solution.

Avelox comes in 400 mg film-coated tablets and a solution for intravenous use. Patients who use Avelox IV will receive the medicine in a slow IV infusion over 60 minutes. The medication label cautions against mixing the drug with other medications in the IV bag or IV line.

Other Fluoroquinolones

Factive, Floxin and their generics accounted for about 1.6 million prescriptions from 2004 to 2010, according to the FDA’s Office of Surveillance and Epidemiology. Then, Janssen Pharmaceuticals discontinued brand name Floxin.

The FDA approved the newest fluoroquinolone, Baxdela, in 2017. Noroxin, Maxaquin, Raxar and Zagam are no longer on the market in the United States in brand name or generics.

Factive
Factive is available in 320 mg tablets and treats chronic bronchitis and pneumonia.
Floxin
Janssen Pharmaceuticals stopped making brand name Floxin and Floxin Otic ear drops, but the drugs are still available as ofloxacin, the generic brand. Ofloxacin is available in 200 mg, 300 mg and 400 mg tablets.
Baxdela
Melinta Therapeutics manufactures Baxdela. The FDA approved it to treat acute bacterial skin and skin structure infections in 2017. The drug comes in 450 mg tablets and 300 mg injections.
Noroxin
Merck discontinued Noroxin in 2014 for unclear reasons. It was available in 400 mg tablets to treat sexually transmitted diseases and urinary tract infections.
Maxaquin
Maxaquin is no longer available in the United States. The usual dosage was 400 mg per day. The drug caused phototoxicity in as many as 44 percent of patients.
Raxar
Glaxo Wellcome withdrew Raxar from the market in 1999 because a safety review had shown the drug could cause adverse cardiac events, The Los Angeles Times reported. In a statement to The Times, the company stated it was “no longer convinced that the benefits of Raxar outweigh the potential risk to patients, given the availability of alternative antibiotics."
Zagam
Mylan Laboratories discontinued Zagam in 2001. The company cited lack of sales, Dr. David C. Hooper wrote in an article for Wolters Kluwer’s medical database, UpToDate. Side effects linked to the drug include phototoxicity and cardiac events. The usual dosage was 200 mg per day to treat acute exacerbations of chronic bronchitis and community-acquired pneumonia.

Drug Interactions

Fluoroquinolones have several drug interactions, and some are fatal, according to the medication labels. For example, taking certain antidiabetic drugs at the same time as these antibiotics can lead to serious hypoglycemia that could result in death. Before taking one of these antibiotics, patients should tell their doctor about all medications, vitamins and supplements they take.

Examples of Drugs that Interact with Fluoroquinolones
Interacting Drug Interaction
Theophylline serious and fatal reactions
Warfarin and other anticoagulant drugs anticoagulation and bleeding
Antidiabetic drugs serious and sometimes fatal hypoglycemia
Phenytoin changes in phenytoin levels, seizure or overdose
Methotrexate methotrexate toxicity
Drugs that prolong QT interval prolonged QT interval, heart problems
Duloxetine duloxetine toxicity
NSAIDs convulsions with high doses of fluoroquinolones

Speak with a pharmacist or doctor for a full list of potential interactions and how to avoid them. For example, antacids, multivitamins, products that contain calcium, iron, or zinc, and dairy products can affect how much of the medicine the body absorbs. So, the medication labels instruct patients to take the drugs at least two to four hours before or six to eight hours after consuming these and other products that contain multivalent cations.

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for seven years. She specializes in fluoroquinolone antibiotics and products that affect women’s health such as Essure birth control, transvaginal mesh and talcum powder. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • American Medical Writers Association (AMWA) Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By
Medically Reviewed By

43 Cited Research Articles

  1. Aldred, K.J. et al. (2014, February 27). Mechanism of Quinolone Action and Resistance. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985860/
  2. Almalki, Z.S. et al. (2017). Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015. Retrieved from https://link.springer.com/article/10.1007/s41669-016-0007-y
  3. American Society of Health-System Pharmacists. (2014, April 29). Norfloxacin Tablets (Noroxin). Retrieved from http://www.ashp.org/menu/DrugShortages/DrugsNoLongerAvailable/bulletin.aspx?id=1099
  4. Bird, S.T. (2013, July 9). Risk of acute kidney injury associated with the use of fluoroquinolones. Retrieved from http://www.cmaj.ca/content/185/10/E475.short
  5. Boyles, S. (2015, October 7). Fluoroquinolones May Increase Aortic Aneurysm Risk. MedPage Today. Retrieved from https://www.medpagetoday.com/Cardiology/Prevention/53950
  6. Brody, J.E. (2012, September 10). Popular antibiotics may carry serious side effects. The New York Times Retrieved from https://well.blogs.nytimes.com/2012/09/10/popular-antibiotics-may-carry-serious-side-effects/
  7. Carr, T. (2016, May 16). Fluoroquinolones too risky for common infections. Retrieved from https://www.consumerreports.org/drugs/fluoroquinolones-are-too-risky-for-common-infections/
  8. Centers for Disease Control and Prevention (CDC). (2010). Quinilones and the Clinical Laboratory. Retrieved from https://www.cdc.gov/HAI/settings/lab/Quinolones-Clinical-Laboratory.html
  9. Centers for Disease Control and Prevention. (2015). Outpatient Antibiotic Prescriptions — United States, 2015. Retrieved from https://www.cdc.gov/antibiotic-use/community/programs-measurement/state-local-activities/outpatient-antibiotic-prescriptions-US-2015.html
  10. Centers for Disease Control and Prevention. (2016). Outpatient Antibiotic Prescriptions — United States, 2016. Retrieved from https://www.cdc.gov/antibiotic-use/community/programs-measurement/state-local-activities/outpatient-antibiotic-prescriptions-US-2016.html
  11. Creative Commons. (n.d.). Avelox. https://pillbox.nlm.nih.gov/assets/large/00085-1733-03_SPLIMAGE30_2619935C.jpg
  12. Creative Commons. (n.d.). Cipro CR. Retrieved from https://pillbox.nlm.nih.gov/assets/large/680840070.jpg
  13. Creative Commons. (n.d.). Levaquin. https://pillbox.nlm.nih.gov/assets/large/50458-0930-20_3E161F70.jpg
  14. DailyMed. (2018, January 12). Levaquin. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be2a14b5-8dc0-473e-8672-96297e20e199&audience=consumer
  15. DailyMed. (2018, October 25). Cipro. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0&audience=consumer#ID_e3c6701b-aac9-4744-a923-b73cbda64d18
  16. Daneman, N. et al. (2015). Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ. Retrieved from https://bmjopen.bmj.com/content/5/11/e010077.full
  17. Etminan, M., Brophy, J.M., & Samii, A. (2014, August 22). Oral fluoroquinolone use and risk of peripheral neuropathy. Retrieved from https://www.neurology.org/content/83/14/1261.short
  18. Grill, M.F., & Maganti, R.K. (2011, September). Neurotoxic effects associated with antibiotic use: management considerations. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175508/
  19. Hooper, D.C. (2001, March 15). Mechanisms of Action of Antimicrobials: Focus on Fluoroquinolones. Retrieved from https://academic.oup.com/cid/article/32/Supplement_1/S9/298541
  20. Hooper, D.C. (2018). Fluoroquinolones. Retrieved from https://www.uptodate.com/contents/fluoroquinolones
  21. Horn, J.R., & Hansten, P.D. (2016, April 11). Fluoroquinolones and steroids: An Achilles heel interaction. Retrieved from https://www.pharmacytimes.com/publications/issue/2016/april2016/fluoroquinolones-and-steroids-an-achilles-heel-interaction
  22. Jones, S.C. et al. (2013, August 20). US-Based Emergency Department Visits for Fluoroquinolone-Associated Hypersensitivity Reactions. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635672/
  23. Kenney, K. (2018, July 17). Drug maker stopped making popular antibiotic Levaquin amid concerns about mental health side effects. Retrieved from https://www.theindychannel.com/news/call-6-investigators/drug-maker-stopped-making-popular-antibiotic-levaquin-amid-concerns-about-mental-health-side-effects
  24. King, D.F. et al. (2000, May 1). New Classification and Update on Quinolone Antibiotics. Retrieved from https://www.aafp.org/afp/2000/0501/p2741.html
  25. Lee, C. et al. (2015, November). Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone. Retrieved from https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2451282
  26. National Institute of Neurological Disorders and Stroke. (n.d.). Peripheral Neuropathy Fact Sheet. Retrieved from https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Peripheral-Neuropathy-Fact-Sheet
  27. Prescribers' Digital Reference. (2008, July 8). Cipro (ciprofloxacin) FDA Drug Safety Communication; Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs. Retrieved from https://www.pdr.net/fda-drug-safety-communication/cipro-oral-suspension-and-tablets?druglabelid=2273&id=5057
  28. ScienceDaily.com. (2013, June 3). Risk of kidney disease doubled with use of fluoroquinolone antibiotics. Retrieved from https://www.sciencedaily.com/releases/2013/06/130603135311.htm
  29. Strauchman, M. & Morningstar, M.W. (2012, October 12). Fluoroquinolone toxicity symptoms in a patient presenting with low back pain. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981197/
  30. Transparency Market Research. (2014). Antibacterial drugs market to top $45B globally in 2019. Retrieved from https://www.centerwatch.com/news-online/2014/03/24/antibacterial-drugs-market-to-top-45b-globally-in-2019/
  31. U.S. Food and Drug Administration. (1999, November 1). Withdrawal of Product: RAXAR( (grepafloxacin HCl) 600 mg Tablets, 400 mg Tablets, and 200 mg Tablets. Retrieved from https://wayback.archive-it.org/7993/20170405182619/https://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab5b.htm
  32. U.S. Food and Drug Administration. (2013, August 15). FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. Retrieved from https://www.fda.gov/media/86575/download
  33. U.S. Food and Drug Administration. (2015, November 5). FDA briefing document. Retrieved from https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet%20DAILY/2015/November/Antimicrobial%20AC%20FDA%20briefing%2011515.pdf
  34. U.S. Food and Drug Administration. (2016, July 26). FDA updates warnings for fluoroquinolone antibiotics. Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm
  35. U.S. Food and Drug Administration. (2016, May 12). FDA Drug Safety Communication. Retrieved from https://www.fda.gov/media/97602/download
  36. U.S. Food and Drug Administration. (2017, September 8). CIPRO (Ciprofloxacin) Use by Pregnant and Lactating Women. Retrieved https://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130712.htm
  37. U.S. Food and Drug Administration. (2017). Highlights of Prescribing Information for Baxdela. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf
  38. U.S. Food and Drug Administration. (2018, December 20). FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics
  39. U.S. Food and Drug Administration. (n.d.). Products on NDA 020635 (Levaquin Discontinued). Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020635
  40. U.S. National Library of Medicine. (2015). Fluoroquinolones. LiverTox. Retrieved from http://livertox.nih.gov/Fluoroquinolones.htm
  41. Wiley, F. (2015, October 19). Antibiotics: Warnings, precautions, side effects & interactions. Retrieved from https://www.everydayhealth.com/antibiotics/guide/
  42. Willman, D. (2000, December 20). RAXAR: Warning on Label Omits Deaths. Retrieved from https://www.latimes.com/nation/la-122001raxar-story.html
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's sponsors support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(877) 361-7006